Can a diabetes drug protect dialysis Patients' hearts?
NCT ID NCT07527390
First seen Apr 22, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This study tests how the diabetes drug canagliflozin (Invokana) spreads through the body in 10 dialysis patients with severe kidney disease. Using PET scans, researchers want to see if the drug reaches tissues like the heart and blood vessels, not just the kidneys. The goal is to understand if these drugs could offer protection beyond the kidneys in people on dialysis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIALYSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Medical Center Groningen
Groningen, Provincie Groningen, 9713 GZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Canagliflozin (Invokana) tablet
What this could lead to
If successful, this could show that SGLT2 inhibitors like canagliflozin reach and protect the heart and blood vessels even in dialysis patients, possibly leading to new treatments for this group.
What could go wrong
This is a very small, early-phase study with only 10 participants, focused on imaging rather than health outcomes. It may not prove any clinical benefit or safety.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.